<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485013</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-080-001</org_study_id>
    <nct_id>NCT04485013</nct_id>
  </id_info>
  <brief_title>TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers</brief_title>
  <official_title>A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab or Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tizona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tizona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to&#xD;
      determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy&#xD;
      (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab&#xD;
      (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TTX-080 is a fully human mAb designed to block the interaction of HLA-G with its known&#xD;
      ligands, ILT2 and ILT4 molecules. The Phase 1a was an open label, multicenter, dose&#xD;
      escalation clinical trial to determine the safety, tolerability, MTD or OBD and the RP2D of&#xD;
      TTX-080 when administered as a single agent. The Phase 1b is a dose expansion of TTX-080&#xD;
      monotherapy and in combination with either pembrolizumab or cetuximab in adult subjects with&#xD;
      advanced refractory/resistant solid malignancies, including Head and Neck squamous cell&#xD;
      carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal cancer (CRC), and triple&#xD;
      negative breast cancer (TNBC). Additionally, the study will seek to evaluate the&#xD;
      pharmacokinetics and immunogenicity of TTX-080, and preliminary efficacy of TTX-080 as a&#xD;
      monotherapy and in combination with pembrolizumab or cetuximab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the anti-tumor activity of TTX-080 by objective response rate [complete response + partial response) for each tumor arm per RECIST 1.1</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, Progression Free Survival per RECIST 1.1</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) as characterized by the incidence, type, frequency, severity (graded according to NCI-CTCAE v5.0), timing, seriousness, and relationship to investigational product, and/or combination therapy, and/or individual approved therapies</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability: The number of cycles of TTX-080 received by patients before discontinuing due to unmanageable drug reactions</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Anti Drug Antibody against TTX-080</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TTX-080</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Cmax for TTX-080</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for TTX-080</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for TTX-080</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1a, Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic colorectal cancer (CRC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR colorectal cancer (CRC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR (KRAS wild type) colorectal cancer (CRC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will enroll subjects with advanced/metastatic triple negative breast cancer (TNBC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTX-080</intervention_name>
    <description>Variable dose (Q3W)</description>
    <arm_group_label>Phase 1a, Monotherapy Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTX-080</intervention_name>
    <description>Specified dose (Q3W)</description>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Specified dose (Q3W)</description>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)</arm_group_label>
    <arm_group_label>Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:&#xD;
&#xD;
          1. Subject with histological diagnosis of advanced/metastatic cancer&#xD;
&#xD;
          2. Age 18 years or older, is willing and able to provide informed consent&#xD;
&#xD;
          3. Evidence of measurable disease&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
        Abbreviated Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy or hypersensitivity to study treatment components. Subjects with a&#xD;
             history of severe hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          2. Use of an investigational agent within 28 days prior to the first dose of study&#xD;
             treatment and throughout the study&#xD;
&#xD;
          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          4. History of severe autoimmune disease&#xD;
&#xD;
          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tizona Therapeutics, Inc.</last_name>
    <phone>888-585-2990</phone>
    <email>clinicaltrials@tizonatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Palma</last_name>
      <phone>203-737-5342</phone>
      <email>Ingrid.palma@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjit Nirmalanandhan</last_name>
      <phone>352-547-1958</phone>
      <email>Sanjit.Nirmalanandhan@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalyn Weaver</last_name>
      <email>Kalyn.Weaver@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Downey</last_name>
      <phone>617-582-8705</phone>
      <email>elizabethe_downey@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Center Oncology Hematology West P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays, M.A. CCRC</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elayne Wesolowsky</last_name>
      <phone>732-235-3253</phone>
      <email>wesoloel@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Rose</last_name>
      <phone>412-647-8587</phone>
      <email>kennaj@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dickinson</last_name>
      <phone>615-524-4203</phone>
      <email>kate.dickinson@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn</last_name>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-580-9521</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLA-G</keyword>
  <keyword>TTX-080</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Squamous Cell Lung Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Lung Adenocarcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

